There was a significant reduction in NT-proBNP levels (MD, -384 (95 % CI, -581.68, -187.72) in ivabradine patients, but no significant change was noted in BNP levels in this group (MD, -72.32; 95 % CI, -263.67, 119.0) The risk reduction in bradycardia and atrial fibrillation among ivabradine users versus non-users were both insignificant (RR, 1.62 (95 % CI, 0.024, 4.83) and RR, 0.93 (95 % CI, 0.014, 12.51), respectively). Here, NPPB is linked to atrial fibrillation.